Creo Medical Group (LSE:CREO) 5-Year EBITDA Growth Rate : 9.60% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Creo Medical Group 5-Year EBITDA Growth Rate?

Creo Medical Group's EBITDA per Share for the six months ended in Dec. 2023 was £-0.03.

During the past 3 years, the average EBITDA Per Share Growth Rate was 21.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Creo Medical Group was 21.00% per year. The lowest was -83.00% per year. And the median was -24.70% per year.

Competitive Comparison of Creo Medical Group's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Creo Medical Group's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Creo Medical Group's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Creo Medical Group's 5-Year EBITDA Growth Rate falls into.

Creo Medical Group 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Creo Medical Group (LSE:CREO) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Creo Medical Group 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Creo Medical Group's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Creo Medical Group (LSE:CREO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Creo Medical Group PLC (LSE:CREO) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH

Website

https://www.creomedical.com

Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy.

Creo Medical Group (LSE:CREO) Headlines

No Headlines